Heart failure is a multifaceted clinical syndrome that impacts over 15 million individuals throughout Europe. It is closely linked with diminished quality of life for patients and substantial healthcare expenditures. Consequently, pioneering AI tools can expedite the initiation of preventive and therapeutic approaches. The EU-funded STRATIFYHF project will develop, validate and implement an AI-driven decision support system through server and mobile-app. This system will serve the purpose of risk stratification, early detection and evaluation of disease progression, effectively addressing the clinical requirements of both primary and secondary care settings. By amalgamating patient-specific demographic and clinical information through state-of-the-art technologies, the system will employ advanced machine learning and computational modeling techniques to formulate AI-powered instruments for precise risk stratification and accurate prognosis. In silico clinical trials are a new paradigm for development of a new drug and medical device. STRATIFYHF project is multiscale modeling of heart failure which considers a comprehensive list of patient specific features as genetic, biological, pharmacologic, clinical, imaging and cellular aspects.